Stem cell-based interventions for the prevention and treatment of germinal matrix-intraventricular haemorrhage in preterm infants

Romantsik, Olga; Bruschettini, Matteo; Moreira, Alvaro; Thébaud, Bernard; Ley, David

doi:10.1002/14651858.cd013201

Cited by 2 publications

(1 citation statement)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…134 However, at the moment, there is no evidence showing benefits of stem cell- or exosomal-based interventions for treatment or prevention of IVH, or any other brain injury, in preterm infants. 135…”

Section: Future Perspectives For Pharmacological Neuroprotection Of H...mentioning

confidence: 99%

Pharmacological Neuroprotection of the Preterm Brain: Current Evidence and Perspectives

Siahanidou

Spiliopoulou

2020

Am J Perinatol

View full text Add to dashboard Cite

Despite improvements in viability, the long-term neurodevelopmental outcomes of preterm babies remain serious concern as a significant percentage of these infants develop neurological and/or intellectual impairment, and they are also at increased risk of psychiatric illnesses later in life. The current challenge is to develop neuroprotective approaches to improve adverse outcomes in preterm survivors. The purpose of this review was to provide an overview of the current evidence on pharmacological agents targeting the neuroprotection of the preterm brain. Among them, magnesium sulfate, given antenatally to pregnant women with imminent preterm birth before 30 to 34 weeks of gestation, as well as caffeine administered to preterm infants after birth, exhibited neuroprotective effects for human preterm brain. Erythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials; however, long-term follow-up of these infants is needed to come to definite conclusions. Further studies are also required to assess whether melatonin, neurosteroids, inhaled nitric oxide, allopurinol, or dietary supplements (omega-3 fatty acids, choline, curcumin, etc.) could be implemented as neuroprotectants in clinical practice. Furthermore, other pharmacological agents showing promising signs of neuroprotective efficacy in preclinical studies (growth factors, hyaluronidase inhibitors or treatment, antidiabetic drugs, cannabidiol, histamine-H3 receptor antagonists, etc.), as well as stem cell- or exosomal-based therapies and nanomedicine, may prove useful in the future as potential neuroprotective approaches for human preterm brain. Key Points

show abstract

Section: Future Perspectives For Pharmacological Neuroprotection Of H...mentioning

confidence: 99%

Pharmacological Neuroprotection of the Preterm Brain: Current Evidence and Perspectives

Siahanidou

Spiliopoulou

2020

Am J Perinatol

View full text Add to dashboard Cite

show abstract

Stem cell-based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants

Romantsik

Moreira

Thébaud

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Stem cell-based interventions for the prevention and treatment of germinal matrix-intraventricular haemorrhage in preterm infants

Cited by 2 publications

References 117 publications

Pharmacological Neuroprotection of the Preterm Brain: Current Evidence and Perspectives

Pharmacological Neuroprotection of the Preterm Brain: Current Evidence and Perspectives

Stem cell-based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants

Contact Info

Product

Resources

About